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Abstract:  The Journal recently incorrectly ascribed cost-effectiveness thresholds to New 
Zealand, alongside other countries. New Zealand has no such thresholds when deciding the 
funding  of  pharmaceuticals.  As  we  fund  pharmaceuticals  within  a  fixed  budget,  and  
cost-effectiveness is only one of nine decision criteria used to inform decisions, thresholds 
cannot be inferred or calculated. Thresholds inadequately account for opportunity cost and 
affordability,  and  are  incompatible  with  budgets  and  maximising  health  gains.  In  New 
Zealand,  pharmaceutical  investments  can  only  be  considered  ‗cost-effective‘  when 
prioritised against other proposals at the time, and threshold levels must inevitably vary with 
available funds and the other criteria. 
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We appreciated Professor Steven Simoens‘ methodological primer for health economic assessment 
(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2800325/,  December  2009  issue)  [1].  However,  we 
need to correct ongoing misperceptions about the supposed role of cost-effectiveness thresholds in 
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New Zealand, as  stated in  the article and elsewhere [1,2]. In fact, different to the other countries 
mentioned, New Zealand overtly and purposely has no cost-effectiveness and cost-utility thresholds for 
pharmaceuticals—either explicitly specified or implicitly able to be determined from past pricing or 
reimbursement decisions.  
Table 1 in the article (at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2800325/table/t1-ijerph-06-
02950/) attempts to describe threshold values use to inform pricing/reimbursement decisions in various 
countries and ostensibly their substantial variation. New Zealand is included in the table, alongside 
Australia,  Canada,  England  and  Wales,  The  Netherlands,  and  the  United  States.  But  in  the  New 
Zealand setting, cost-effectiveness  is  only one of nine decision criteria, and medicines are funded 
within a fixed budget; so thresholds cannot be inferred and calculated for this country.  
To explain, New Zealand‘s Pharmaceutical Management Agency (PHARMAC), the Government 
agency that decides which medicines in the community will be funded, is required by legislation ‗to 
secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably 
achievable from pharmaceutical treatment and from within the funding provided.’ [emphasis added].  
This means that we are required to keep spending on community pharmaceuticals within a capped 
budget. To decide best outcomes, PHARMAC has nine decision criteria that include health needs, 
availability  of  other  treatments,  clinical  benefits  and  risks,  and  budgetary  impacts,  amongst  other 
things;  the  full  criteria  are  outlined  at  http://www.pharmac.govt.nz/ 
operational_policies_and_procedures.asp;  for  this  reason  alone  there  can  be  no  cost-effectiveness 
threshold.  Net  cost-effectiveness  to  the  health  sector  overall  [3]  by  itself  does  not  determine  the 
outcome; one proposal may be more cost effective than another but rate poorly on other decision 
criteria  and  thus  may  not  be  funded.  In  the  New  Zealand  setting,  any  proposal  to  invest  in  a 
pharmaceutical  can  only  be  considered  ‗cost-effective‘  when  prioritised  against  other  proposals  at  
the time. 
Given the binding nature of the fixed budget [4], and all things being equal, what investments others 
might  or  might  not  broadly  consider  to  be  ‗cost-effective‘  will  vary  with  the  amount  of  funding 
available. This is not just in terms of the total budget each year, but the available budget and forecast at 
any point in time. Consequently the putative cost-effectiveness of new investments in New Zealand has 
varied widely each year – reflecting both the mix of investment opportunities and the funding available 
at  the  time;  see  PHARMAC‘s  Prescription  for  Pharmacoeconomic  Analysis  (PFPA)  at 
http://www.pharmac.govt.nz/healthpros/EconomicAnalysis/pharmacoeconomics [5]. 
Thresholds do not explicitly consider opportunity cost (health benefits forgone by choosing not to 
spend finite resources on alternatives), as they consider interventions in isolation to other potential 
investments  [6,7]—see  http://www.nzma.org.nz/journal/118-1223/1690.  Fixing  thresholds  provides 
little incentive to price new technologies competitively—forgoing the potential health gains from lower 
prices freeing funds for other heath interventions. As Professor Simoens mentions, thresholds do not 
consider affordability. These problems mean that thresholds jeopardise the chances to maximise health 
gains [4,8].  
In addition, when taken at face value, the data in Professor Simoens‘ Table 1 suggests a ‗threshold‘ 
in New Zealand equivalent to Euros€1,400–7,200 per QALY, which is lower than the other countries 
listed. Aside from the fact that no threshold exists, this value quoted is also incorrect. The source data Int. J. Environ. Res. Public Health 2010, 7                 
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(graph on page 18 of the PFPA [5]) are the patient volume-weighted cost per QALYs for investments 
made in each of the seven financial years 1998/99 to 2004/05 (the NZ$3,000–15,000/QALY stated in 
Professor Simoens‘ table). This weighting takes the cost per QALY measured for each investment in a 
particular year, and weights them by their numbers of new patients, to gain the overall weighted cost 
per QALY for that year. However, the volume weighting in any year will be lower than the crude 
average  cost/QALY  in  that  year—because  more  cost-effective  investments  in  general  affect  more 
people, improving the overall year‘s cost-effectiveness.  
Over nine years, the range of cost-effectiveness estimates for PHARMAC‘s investments has ranged 
between NZ$−40,000 (net cost savings to the health sector for health gains) to over NZ$+200,000 per 
QALY  (€−20,000  to  +100,000)  (see  Figure  1).  If  using  a  threshold  approach,  New  Zealand‘s 
―threshold‖ would then be €100,000 (NZ$200,000) per QALY—which clearly is not the case.  
 
Figure 1. Annual variation in the cost-effectiveness of PHARMAC investments, 1998/99 
to 2006/07. 
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Hence, for the record, in New Zealand there is no threshold below which a pharmaceutical is 
considered ‗cost-effective‘; value relates to nine decision criteria, not one; and having a threshold is 
incompatible with a fixed budget—however big—because we could never guarantee to fund everything 
that met a threshold. 
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